Aus Seekingalpha: Product Pipeline
Gilead has 35 product in its development pipeline as of December 31st, 2017, including 4 HIV/AIDS drugs (1 in final approval stages), 7 liver disease drugs (1 in phase 3 trials), 15 hematology/oncology drugs (2 in phase 3 trials), 8 inflammation/respiratory drugs (3 in phase 3 trials) and 1 drug to treat the Ebola virus which is currently in phase 2 trials.
The company expects significant NASH product results from Phase 2 trials in H1 of 2018, alongside HIV treatments studies currently in Phase 1 and 3 trials.
Gilead's existing drugs include blockbuster HIV and hepatitis C drugs and others which generate the majority of current revenues, even with some being on decline in recent quarters due to market saturation.
Vielleicht wird endlich einmal diese Pipeline honoriert? Hoffen wir, dass sich unsere Geduld auszahlt. Gerade stehen wir bei USD 80,70. Da sollte noch etwas mehr gehen.
|